 |
January 31, 2011
Dr Luca Toschi speaks about molecular biomarkers and acquired resistance to new target agents. A number of speakers at ESMO 2010 have stressed the important of collecting tissue samples before ...
|
 |
January 31, 2011
Prof. Giorgio Parmiani speaks about the potential benefit of new anti-BRAF drugs and discusses patient response and side effects seen in patients treated with ipilimumab. Prof. Parmiani explains ...
|
 |
January 31, 2011
Prof Fausto Roila speaks about two studies presented at ESMO 2010. The first of these involved 'Balloon Kyphoplasty', a new minimally invasive procedure for painful vertebrae ...
|
 |
January 27, 2011
Prof Matti Aapro (University of Geneva) Prof Joachim Fandrey (Essen University, Germany) Prof Dirk Schrijvers (Middelheim Hospital, Antwerp) and Prof Anders Österborg (Karolinska Institutet, ...
|
 |
January 25, 2011
Prof. Berksoy Sahin speaks in Turkish about the challenges faced in treating soft tissue sarcoma in Turkey.
|
 |
January 25, 2011
Prof Joan Albanell Mestres speaks in Spanish about his research into the clinical utility of Oncotype DX testing in breast cancer patients. This test was used on a group of oestrogen ...
|
 |
January 25, 2011
Dr Alexander Fedenko speaks in Russian about the work of the East European Sarcoma Group and the challenges faced in treating soft tissue sarcoma in Russia.
|
 |
January 24, 2011
Prof Joan Albanell Mestres speaks about his research into the clinical utility of Oncotype DX testing in breast cancer patients. This test was used on a group of oestrogen receptor-positive ...
|
 |
January 24, 2011
Prof Christian Marth discusses whether clinicians should continue to follow-up ovarian cancer patients using the CA-125 tumour marker. A recent study has shown that early treatment in response to ...
|
 |
January 20, 2011
The Tenovus Sing For Life Choir perform at the National Cancer Resarch Institute Conference at the BT Convention Centre, Liverpool, 7.11.10. A truly remarkable choir made up of people who have ...
|
 |
January 19, 2011
Dr Perez talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about a debate she took part in on the use of Avastin (Bevacizumab) for metastatic breast cancer and also her recent ...
|
 |
January 19, 2011
Prof Workman talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium, explaining what molecular chaperones are and their role in causing cancer. He discusses the first generation of ...
|
 |
January 19, 2011
Dr Faratian talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about using 'systems biology' to improve trial design and treatment. In this case systems biology ...
|
 |
January 19, 2011
Prof Robertson talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about fulvestrant (500mg dose) in comparison to the aromatase inhibitor, anastrozole, when used as a first-line ...
|
 |
January 19, 2011
Prof Kantel talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about his work with circulating tumour cells, and the potential for clinical application. A simple blood test can ...
|
 |
January 19, 2011
Nancy Lin discusses the session she chaired at the 2010 San Antonio Breast Cancer Symposium on metastases in breast cancer, and specifically her talk on trying to tackle cancer that has spread to ...
|
 |
January 19, 2011
Prof Garth Powis talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about how causing stress to tumours by increasing hypoxia to reduce tumour resistance to chemotherapy and ...
|
 |
January 19, 2011
Professor Michael Gnant talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium. Zometa, an osteoporosis drug from Novartis, failed to improve disease free survival of early breast ...
|
 |
January 19, 2011
Prof Charles Perou talks to ecancertv at the 2010 San Antonio Breast Cancer Symposium about next generation sequencing and whole genome sequencing and their application to breast cancer. He ...
|
 |
January 18, 2011
For patients with breast cancer and bone metastases, denosumab delayed skeletal-related side effects five months longer compared to those on zoledronic acid, according to results presented at the ...
|
|
|
|
|
|
Featured
Content
Featuring websites that enhance the internet user’s experience.
|